Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

10.4K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.4K
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

129
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
129

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Emergence of ceftazidime-avibactam resistance mediated by KPC variants KPC-71 and KPC-78 in ST463 <i>Pseudomonas aeruginosa</i>.

Microbiology spectrum·2026
Same author

The ZmGF14-6-ZmCDC48 module controls endosperm cell proliferation and kernel weight in maize.

Journal of genetics and genomics = Yi chuan xue bao·2026
Same author

Post-traumatic stress status among emergency department nurses during the winter H1N1 influenza season and correlations with burnout, coping, resilience, and support.

Frontiers in psychology·2026
Same author

LaeA Orchestrates Iron-Heme Supply and P450 Catalytic Efficiency for Enhanced Echinocandin B Biosynthesis in Aspergillus nidulans.

Biotechnology journal·2026
Same author

Bidirectional redox-modulating vanadium carbide-integrated smart microneedles for infected wound healing.

Redox biology·2026
Same author

Polymer-Based Biomaterials for Local Therapy in Cervical Cancer: A Mini-Review.

Polymers·2026

Related Experiment Video

Updated: May 7, 2026

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

331

Comparative analysis for optimal LSD1 inhibitors evaluation techniques: pros and cons.

Qiange Yin1,2, Congcong Ma1, Xiaoying Zhao1

  • 1State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education of China, Key Laboratory of Henan Province for Small Molecule Drug Discovery and Application, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.

Journal of Pharmaceutical Analysis
|May 6, 2026
PubMed
Summary

Lysine-specific demethylase 1 (LSD1) is a cancer target, but its dual role poses challenges. This study reviews methods to find new therapies targeting LSD1's scaffolding functions, not just its enzymatic activity.

Keywords:
LSD1LSD1 inhibitors screeningLSD1 scaffold inhibitors

More Related Videos

Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays
11:17

Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays

Published on: June 13, 2019

6.5K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

17.5K

Related Experiment Videos

Last Updated: May 7, 2026

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

331
Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays
11:17

Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays

Published on: June 13, 2019

6.5K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

17.5K

Area of Science:

  • Oncology
  • Biochemistry
  • Drug Discovery

Background:

  • Aberrant expression of lysine-specific demethylase 1 (LSD1) is linked to various cancers, making it a key therapeutic target.
  • LSD1's dual role as a catalytic enzyme and a scaffolding protein in chromatin remodeling complicates inhibitor development.
  • Emerging research highlights LSD1's non-enzymatic functions, suggesting disruption of protein-protein interactions as a novel therapeutic strategy.

Purpose of the Study:

  • To critically review and compare current screening platforms and binding affinity assays for identifying LSD1 inhibitors.
  • To focus on technologies capable of discovering inhibitors targeting LSD1's scaffolding functions.
  • To accelerate the development of next-generation LSD1-targeted cancer therapies.

Main Methods:

  • Systematic evaluation of existing technologies for LSD1 inhibitor screening.
  • Comparative analysis of binding affinity assays.
  • Focus on assays suitable for identifying LSD1 scaffold inhibitors.

Main Results:

  • Provides a comprehensive overview of current screening and assay technologies relevant to LSD1.
  • Highlights the limitations and strengths of different approaches for targeting LSD1's scaffolding role.
  • Identifies key technologies for advancing the discovery of novel LSD1 inhibitors.

Conclusions:

  • Disrupting LSD1's protein-protein interactions offers a promising therapeutic avenue in oncology.
  • Systematic evaluation of screening platforms is crucial for identifying effective LSD1 scaffold inhibitors.
  • This work aims to guide the development of more translatable LSD1-targeted therapies.